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Abstract
Background: In a recently published 24-week maintenance study of olanzapine long-acting injection (LAI) in
schizophrenia (Kane et al., 2010), apparent dose-associated changes were noted in both efficacy and safety
parameters. To help clinicians balance safety and efficacy when choosing a dose of olanzapine LAI, we further
studied these changes.
Methods: Outpatients with schizophrenia who had maintained stability on open-label oral olanzapine for 4 to
8 weeks were randomly assigned to “low” (150 mg/2 weeks; N = 140), “medium” (405 mg/4 weeks; N = 318), or
“high” (300 mg/2 weeks; N = 141) dosages of olanzapine LAI for 24 weeks. Potential relationships between dose
and several safety or efficacy measures were examined via regression analysis, the Jonckheere-Terpstra test
(continuous data), or the Cochran-Armitage test (categorical data).
Results: Safety parameters statistically significantly related to dose were mean weight change (low: +0.67 [SD =
4.38], medium: +0.89 [SD = 3.87], high: +1.70 [SD = 4.14] kg, p = .024; effect size [ES] = 0.264 high vs. low dose),
mean change in prolactin (low: -5.61 [SD = 12.49], medium: -2.76 [SD = 19.02]), high: +3.58 [SD = 33.78] μg/L,
p = .001; ES = 0.410 high vs. low dose), fasting triglycerides change from normal at baseline to high (low: 3.2%,
medium: 6.0%, high: 18.9%, p = .001; NNT = 7 high vs. low dose) and fasting high-density lipoprotein cholesterol
change from normal at baseline to low (low: 13.8%, medium: 19.6%, high: 30.7%, p = .019; NNT = 6 high vs. low
dose). Efficacy measures significantly related to dose included Positive and Negative Syndrome Scale total score
mean change (low: +2.66 [SD = 14.95], medium: -0.09 [SD = 13.47], high: -2.19 [SD = 13.11], p <.01; ES = 0.356 high
vs. low dose), relapse rate (low: 16%, medium: 10%, high: 5%, p = .003; NNT = 9 high vs. low dose), all-cause
discontinuation rate (low: 36%, medium: 30%, high: 24%, p = .037; NNT = 9 high vs. low dose), and rate of
discontinuation due to efficacy-related reasons (low: 20%, medium: 14%, high: 6%, p <.001). Time to all-cause
discontinuation (p = .035) and time to relapse (p = .005) were also significantly related to dose.
Conclusions: Analyses of several safety and efficacy parameters revealed significant associations with dose of
olanzapine LAI, with the highest dose generally showing greater efficacy as well as greater adverse changes in
metabolic safety measures. When considering olanzapine LAI, as with all antipsychotics, it is important to carefully
consider the potential benefits and risks for an individual patient.
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Olanzapine long-acting injection (LAI) has been studied
in both the short-term [1] and long-term [2] treatment of
schizophrenia. In a 24-week maintenance study of olan-
zapine LAI, apparent dose-associated changes were
observed for both safety and efficacy parameters [2].
Some previous studies in patients treated with oral olan-
zapine have found an association between olanzapine
plasma concentrations and changes in some metabolic
parameters [3,4], as well as differences in changes in effi-
cacy and safety parameters in a sample including patients
treated with doses greater than 20 mg/day [5]. Consider-
ing these reports, the observed dose-associated changes
were not completely unexpected and warranted further
investigation. Reports of dose-associated changes invol-
ving other depot antipsychotics are sparse. In older, typi-
cal depots such as haloperidone decanoate, dose-related
extrapyramidal symptoms (EPS) have long been observed
[6]. Among atypical depots, risperidone long-acting injec-
tion has been reported as having dose-related changes for
both weight and EPS, similar to that seen with oral ris-
peridone [7]. Based on a limited number of studies, pali-
peridone palmitate may also have dose-related changes
for weight, EPS, and prolactin [8].
Although the US prescribing information for olanza-
pine LAI [9] provides dosing recommendations based
on the desired or target oral olanzapine dose, there is
currently little information available to help clinicians
balance safety and efficacy when selecting a dose. To
that end, we conducted a further investigation of the
dose-associated changes observed in the 24-week main-
tenance study mentioned above [2].
This article reports the results of post hoc analyses of
a 24-week maintenance study of olanzapine LAI [2]
examining the potential association between olanzapine
LAI dose and several safety and efficacy parameters of
clinical interest. Based on inspection of results pre-
v i o u s l yr e p o r t e d[ 2 ] ,w eh y p o t h e s i z e dt h a ts i g n i f i c a n t
dose-associated changes would be identified for both
safety and efficacy parameters in this olanzapine LAI
clinical trial.
Method
A complete description of the clinical trial including the
study design and patient population are found in the
p r i m a r yp u b l i c a t i o n[ 2 ] .W ep r o v i d eo n l yt h em e t h o d o -
logical details pertinent to the post hoc analysis reported
here. The study was conducted in accordance with the
ethical principles set forth in the Declaration of Hel-
sinki, good clinical practices (GCPs), and applicable laws
and regulations. For each investigational site, ethical
review boards provided written approval of the study
protocol and the informed consent document.
Patients
All patients from the 24-week maintenance study [2]
who had been randomly assigned to 1 of 3 therapeutic
doses of olanzapine LAI (N = 599) were included in
these analyses. Patients were 18 to 75 years of age with
a diagnosis of schizophrenia according to the DSM-IV
or DSM-IV-TR.
Measures
Safety/tolerability measures investigated included inci-
dence of unsolicited treatment-emergent adverse events
occurring in ≥5% of patients or with between-groups
p <.10, mean changes in weight and certain laboratory
parameters (i.e., fasting glucose, lipids, and prolactin
measures), and treatment-emergent categorical changes
in these laboratory values [10,11].
Efficacy measures included time to relapse and rate of
relapse. Relapse was defined a priori as 1) an increase of
any Brief Psychiatric Rating Scale (BPRS) [12] positive
symptom item to a score >4, with an absolute increase
≥2 for the specific item since randomization; or 2) an
increase of any BPRS positive symptom item to a score
>4, with an absolute increase ≥4 on the positive symp-
tom subscale since randomization; or 3) hospitalization
as the result of worsening of positive psychotic symp-
toms. Other efficacy/effectiveness measures included
mean change in Positive and Negative Syndrome Scale
(PANSS) [13] total, positive, and negative scores; time to
all-cause discontinuation; rate of overall discontinuation;
and rate of discontinuation due to efficacy-related rea-
sons. “Efficacy-related reasons” was defined as disconti-
nuation due to lack of efficacy or discontinuation due to
any psychiatric adverse event (e.g., “schizophrenia,”
“paranoid disorder,” etc.).
Procedures and Dosing
Outpatients with schizophrenia who had maintained sta-
bility on open-label oral olanzapine for 4 to 8 weeks
were randomly assigned to receive 1 of the following
olanzapine LAI dosages for 24 weeks: 1) 150 mg every
2 weeks, hereafter referred to as “low” (N = 140), 2)
405 mg every 4 weeks, hereafter referred to as “medium”
(N = 318), or 3) 300 mg every 2 weeks, hereafter
referred to as “high” (N = 141). The approximate oral
equivalents for these olanzapine LAI dosages are 10 mg/
day for the low dose, 15 mg/day for the medium dose,
and 20 mg/day for the high dose.
Statistical Analyses
The primary objective of these post hoc analyses was to
examine the potential relationship between different
olanzapine LAI doses and changes in safety and efficacy
parameters. For continuous (or mean change) data, we
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between dose and the endpoint assessments of PANSS
total score, prolactin, weight, and fasting glucose and
lipids measures. These endpoint assessments were the
mean change from baseline using the last-observation-
carried forward (LOCF) method. Patients were only
included in the analysis if they had a baseline and at
least one post-baseline assessment. To check the robust-
ness of the analyses, we also utilized the non-parametric
Jonckheere-Terpstra [14] test for the safety measures
including mean changes in weight, as well as fasting glu-
cose, lipids, and prolactin measures. Effect sizes between
doses were estimated as the difference of the least-
squares means divided by the square root of model resi-
dual variance. Least-squares estimates were obtained
from the following ANOVA model: change from base-
line = therapy + geographic region.
For categorical data, we used the Cochran-Armitage
test [15] for incidence of treatment-emergent adverse
events, treatment-emergent categorical changes in pro-
lactin, weight, and fasting glucose and lipids (using
American Diabetes Association and National Cholesterol
Education Program criteria) [11,16], and relapse and dis-
continuation rates. For time-to-event measures, we used
Kaplan-Meier survival method and compared potential
dose effects using the log-rank test. Finally, we calcu-
lated number needed to treat (NNT) and number
needed to harm (NNH) values for the categorical safety
and efficacy outcomes.
Unless otherwise specified, analyses were performed
on a subset of the original intent-to-treat population;
that is, those patients in the 3 treatment groups (3 clini-
cal olanzapine LAI doses) from the original study. Statis-
tical significance was defined as 2-tailed p <.05. Because
the purpose of the analyses was to detect a potential
relationship between changes in certain efficacy and
safety variables and 3 different study drug doses, no
type I error adjustments for multiplicity were performed.
Results
Safety and Tolerability Analyses
As reported in the published manuscript [2], the 3 dose
groups did not significantly differ on any baseline demo-
graphic or illness characteristics, with the exception of
mean baseline PANSS total score (high-dose group sig-
nificantly higher at baseline than the medium-dose
group, 56.8 vs. 55.1).
Table 1 presents the incidence and the Cochran-Armi-
tage trend test p-values for treatment-emergent adverse
events occurring in ≥5% of patients in the dose groups,
or with between-groups p <.10. Only “increased appe-
tite” showed a significant dose association, the incidence
of which increased with increasing dose.
Table 2 provides the mean changes in weight and in
several fasting glucose, lipids, and prolactin laboratory
measures, along with results of the trend tests from
both a regression analysis and the Jonckheere-Terpstra
test. Significant dose-associated changes were identified
f o rw e i g h ta n df o rp r o l a c t i n ,b o t ho fw h i c he x h i b i t e d
mean increases with increasing dose. The resulting scat-
terplots, trendlines, and regression equations are shown
in Figure 1 for weight and in Figure 2 for prolactin.
Note that in these equations, “dose” refers to the calcu-
lated oral equivalent daily dose (i.e., 10.7, 14.5, or
21.4 mg/day), not the actual injected dose.
Table 3 presents the incidence of categorical changes
in these laboratory measures at endpoint, along with
results of the Cochran-Armitage trend tests. Significant
dose associations were identified for fasting high-density
lipoprotein (HDL) cholesterol normal at baseline to low
at endpoint and fasting triglycerides normal at baseline
to high at endpoint, the incidence of which increased
with increasing dose.
Efficacy and Effectiveness Analyses
Figure 3 presents the Kaplan-Meier survival curves by
dose group for time to relapse. The high-dose group
had a significantly longer time to relapse than the low-
dose group. Rates of relapse (low: 16%, medium: 10%,
high: 5%) also showed a significant dose association
based on the Cochrane-Armitage test (p = .003), indicat-
ing declining relapse rates with increasing dose.
A statistically significant dose association based on
regression analysis was identified for baseline-to-end-
point mean change in PANSS total score (low: +2.66 [SD
= 14.95], medium: -0.09 [SD = 13.47], high: -2.19 [SD =
13.11], p <.01) and PANSS positive score (p = .04), but
not PANSS negative score (p = .08). The resulting scat-
terplot, trendline, and regression equation are shown in
Figure 4. Mean PANSS total scores declined with increas-
ing dose, indicated by the negative slope. Effect sizes for
PANSS total were: 0.356 high vs. low, 0.203 medium vs.
low, and 0.152 high vs. medium. Effect sizes for PANSS
positive were 0.258 high vs. low, 0.167 medium vs. low,
and 0.091 high vs. medium.
Figure 5 presents discontinuation rates, both overall
(low: 36%, medium: 30%, high: 24%, p = .037) and due
to efficacy-related reasons (low: 20%, medium: 14%,
high: 6%, p <.001). Significant dose associations were
identified for both of these measures based on the
Cochran-Armitage test, indicating declining discontinua-
tion rates with increasing dose. Figure 6 presents the
Kaplan-Meier survival curves by dose group for time to
all-cause discontinuation. The high-dose group had a
significantly longer time to all-cause discontinuation
than the low-dose group.
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(NNH) Analyses
For changes in HDL cholesterol normal at baseline to
low at endpoint, the NNH was 6 (95% CI: 4 to 43)
when comparing high- and low-dose groups. This NNH
value indicates that for every 6 patients treated with the
high dose instead of the low dose for 24 weeks, 1 addi-
tional HDL change (normal to low) can be expected.
For changes in triglycerides from normal at baseline to
high at endpoint, the NNH was 8 (95% CI: 5 to 64)
when comparing the high-dose with the medium-dose
group and 7 (95% CI: 4 to 24) when comparing the
high-dose with the low-dose group. These NNH values
indicate that 1 additional triglycerides change (normal
to high) can be expected to occur for every 8 patients
treated with the high dose instead of the medium dose,
or for every 7 patients treated with the high dose instead
of the low dose.
The NNT for relapse rate was 20 (95% CI: 11 to 294)
when comparing the high-dose with the medium-dose
group and 9 (95% CI: 6 to 24) when comparing the
high-dose with the low-dose group. These NNT values
indicate that 1 less relapse can be expected for every
20 patients treated with the high dose instead of the
medium dose for 24 weeks; likewise, 1 less relapse can
be expected for every 9 patients treated with the high
dose instead of the low dose. As with relapse rate, the
NNT for overall discontinuation rate comparing high
dose and low dose was 9 (95% CI: 5 to 103), indicating
that for every 9 patients treated with the high dose
instead of the low dose, 1 additional patient is expected
not to discontinue treatment. The NNT for discontinua-
tion due to efficacy-related reasons was 8 (95% CI: 5 to
18) for high versus low dose and 13 (95% CI: 8 to 46)
for high versus medium dose.
Additional variables analyzed for NNT or NNH were
not significant.
Discussion
These analyses further investigated apparent dose-asso-
ciated changes for both safety and efficacy variables
observed in a 24-week maintenance study of olanza-
pine LAI in patients with schizophrenia [2]. In this
post hoc analysis, we identified statistically significant
dose-associated changes for several measures, including
safety/tolerability variables (incidence of increased
appetite, mean changes in weight and prolactin, cate-
gorical changes in HDL cholesterol and triglycerides)
and efficacy/effectiveness measures (i.e., relapse,
PANSS change, and discontinuation). When making a
decision about the dosage of olanzapine LAI, both
safety and efficacy must be considered, along with
other factors. This analysis suggests that higher doses
of olanzapine LAI may be associated with both clini-
cally desirable efficacy outcomes, including fewer
relapses and longer time to discontinuation, and disad-
vantageous changes in certain safety outcomes, such as
greater weight gain.
Prior studies have inconsistently found dose-associated
changes in safety or efficacy measures for oral olanzapine.
Several articles have reported a lack of dose-associated
changes for oral olanzapine within the labeled dose range
[4,17,18]; however, others have identified differences in
safety and/or efficacy changes between doses within the
labeled dose range and a higher dose which appear to be
related to olanzapine plasma concentrations [3,5]. Why
did the current analysis find a dose relationship? The
true fixed-dose design of the study used for this analysis
w a sm o r es u i t e df o rad o s ec o m p a r i s o nt h a nw e r es o m e
previous oral olanzapine studies, which allowed for small
dose adjustments (increases and decreases) within the
fixed dose designs. Additionally, the nature of the injec-
tion itself provided for a more controlled dose compari-
son. Olanzapine LAI delivers a continuous, consistent
dose of olanzapine to the system, so any variations due to
Table 1 Treatment-emergent adverse events occurring in ≥5% of patients or with between-groups p <.10
OLZ LAI 150
(N = 140)
OLZ LAI 405
(N = 318)
OLZ LAI 300
(N = 141)
Overall p-value
a Cochran-Armitage Test p-value
Anxiety 5 (3.57%) 17 (5.35%) 7 (4.96%) .767 .686
Headache 7 (5.00%) 9 (2.83%) 3 (2.13%) .355 .216
Increased appetite 1 (0.71%) 3 (0.94%) 5 (3.55%) .080 .031
Insomnia 11 (7.86%) 23 (7.23%) 9 (6.38%) .871 .632
Nasopharyngitis 8 (5.71%) 11 (3.46%) 7 (4.96%) .442 .947
Schizophrenia 6 (4.29%) 3 (0.94%) 2 (1.42%) .047 .165
Somnolence 8 (5.71%) 10 (3.14%) 5 (3.55%) .367 .467
Weight increased 12 (8.57%) 16 (5.03%) 15 (10.64%) .071 .267
Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral
equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day
(N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
aTest of overall group differences based on Fisher’s exact test.
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Page 4 of 10Table 2 Mean changes in weight and laboratory values
OLZ LAI 150
(N = 140)
Mean (SD)
OLZ LAI 405
(N = 318)
Mean (SD)
OLZ LAI 300
(N = 141)
Mean (SD)
R-
Square
Regression
Slope
Regression
p-value
Jonckheere-
Terpstra p-value
Effect Sizes
High vs. Low
(95% C.I.)
Medium vs. Low
(95% C.I.)
High vs. Medium
(95% C.I.)
Weight (kg) 0.67 (4.38) 0.89 (3.87) 1.70 (4.14) 0.0086 0.10 .024 .034 0.264 0.063 0.201
in lbs: 1.47 (9.64) 1.96 (8.51) 3.74 (9.11)
Fasting glucose
(mmol/L)
0.14 (1.36) 0.17 (1.29) 0.22 (1.19) 0.0005 0.01 .642 .092 0.049 0.016 0.033
in mg/dL: 2.52 (24.50) 3.06 (23.24) 3.96 (21.44)
Fasting HDL (mmol/L) -0.00 (0.22) 0.00 (0.24) -0.05 (0.24) 0.0064 -0.01 .094 .215 0.196 0.022 0.218
in mg/dL: -0.00 (8.49) 0.00 (9.27) -1.93 (9.27)
Fasting LDL (mmol/L) -0.04 (0.57) -0.07 (0.64) 0.02 (0.73) 0.0015 0.01 .423 .169 0.078 0.041 0.119
in mg/dL: -1.54 (22.01) -2.70 (24.71) 0.77 (28.19)
Fasting total
cholesterol (mmol/L)
-0.12 (0.65) -0.07 (0.73) 0.01 (0.78) 0.0037 0.01 .199 .240 0.165 0.065 0.100
in mg/dL: -4.63 (25.10) -2.70 (28.19) 0.39 (30.12)
Fasting triglycerides
(mmol/L)
-0.18 (1.84) -0.03 (1.23) 0.03 (1.19) 0.0022 0.02 .324 .958 0.147 0.107 0.039
in mg/dL: -15.93 (162.83) -2.65 (108.85) 2.65 (105.31)
Prolactin (μg/L):
All patients -5.61 (12.49) -2.76 (19.02) 3.58 (33.78) 0.0209 0.87 .001 <.001 0.410 0.127 0.283
Females -8.27 (16.1) -2.86 (30.31) 4.33 (23.16) 0.0294 1.16 .026 <.001 0.493 0.212 0.281
Males -3.88 (9.17) -2.72 (9.65) 3.16 (38.56) 0.0159 0.70 .025 .018 0.347 0.047 0.300
Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group
receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate
oral equivalent 20 mg/day (N = 141); HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol.
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wise, are eliminated, allowing for a closer link between
prescribed dose and systemic concentrations. While plau-
sible hypotheses, additional research is needed to verify
these findings in other studies and to explore related fac-
tors. Experience in clinical practice, outside of registra-
tion trials, may also provide needed perspective.
The NNT and NNH analyses provide important clini-
cal insight into selecting doses. There were both advan-
tages and disadvantages to using the highest dose rather
than the lowest dose, and also for using the highest
dose versus the medium dose. We did not find signifi-
cant NNT or NNH values comparing low dose with
medium dose, suggesting that any clinical differences
between these 2 doses could be difficult to detect in
practice. It should be noted that in addition to the 3
doses described here, there are 2 other doses of olanza-
pine LAI that have been studied (300 mg every 4 weeks
and 210 mg every 2 weeks, which are roughly equivalent
to 150 mg every 2 weeks and 405 mg every 4 weeks,
respectively). In addition, the doses described in this
analysis are for maintenance treatment; prescribers
should refer to the medication labeling for recommen-
dations on initiating therapy with olanzapine LAI.
There are some important limitations to the current
analyses. First, these analyses were conducted post hoc
in a single clinical trial and therefore should be consid-
ered exploratory. Next, it is important to note that
because this was a maintenance study, patients in this
analysis had been taking open-label oral olanzapine for
4 to 8 weeks prior to baseline to establish clinical stabi-
lity; thus, any adverse events occurring during that lead-
in phase are not represented here (although lead-in
phase data were collected and are reported in the pri-
mary manuscript [2]). Therefore, certain safety signals,
such as weight gain or metabolic changes, may be
underestimated in this analysis. At the same time, as we
did not correct for multiple comparisons, some safety
signals could be false positives occurring due to chance
alone. Another consideration is that the very low dose
of olanzapine LAI, 45 mg/4 weeks (approximately 1.6
mg/day oral equivalent) was not included. Whereas
inclusion of this very low dose would have allowed an
examination of trends across a much wider dosing
range, this dose was shown to be non-therapeutic in the
s t u d y[ 2 ] ,i su n l i k e l yt ob eu tilized in clinical practice,
and could lead to a distortion of the trends in the true
dosing range of olanzapine LAI. Finally, one aspect of
Table 3 Categorical changes in weight and laboratory values at endpoint
OLZ LAI 150 n/N
(%)
OLZ LAI 405 n/N
(%)
OLZ LAI 300 n/N
(%)
Cochran-Armitage p-
value
Weight ≥7% gain 17/140 (12.14) 34/315 (10.79) 24/140 (17.14) .127
≥7% loss 9/140 (6.43) 13/315 (4.13) 7/140 (5.00) .720
Fasting glucose Normal to borderline 14/75 (18.67) 37/176 (21.02) 25/89 (28.09) .121
Normal/borderline to high 5/106 (4.72) 6/244 (2.46) 4/108 (3.70) .855
Normal to high 1/75 (1.33) 2/176 (1.14) 0/89 (0) .311
Borderline to high 4/31 (12.90) 4/68 (5.88) 4/19 (21.05) .320
Fasting HDL Normal to low 8/58 (13.79) 26/133 (19.55) 19/62 (30.65) .019
Fasting LDL Normal to borderline 6/26 (23.08) 15/66 (22.73) 5/18 (27.78) .702
Normal to high 0/26 (0) 0/66 (0) 0/18 (0) —————
Borderline to high 6/53 (11.32) 14/129 (10.85) 9/73 (12.33) .804
Fasting total
cholesterol
Normal to borderline 9/48 (18.75) 15/133 (11.28) 10/51 (19.61) .607
Normal to high 0/48 (0) 2/133 (1.50) 2/51 (3.92) .127
Borderline to high 4/34 (11.76) 13/65 (20.00) 5/35 (14.29) .959
Fasting triglycerides Normal to borderline 13/62 (20.97) 17/133 (12.78) 9/53 (16.98) .713
Normal to high 2/62 (3.23) 8/133 (6.02) 10/53 (18.87) .001
Normal to extremely high 0/62 (0) 0/133 (0) 1/53 (1.89) .082
Borderline to high 3/14 (21.43) 11/38 (28.95) 3/18 (16.67) .556
Borderline to extremely
high
0/14 (0) 0/38 (0) 1/18 (5.56) .114
Prolactin Normal to high (females) 2/17 (11.76) 9/42 (21.43) 7/21 (33.33) .112
Normal to high (males) 4/49 (8.16) 16/116 (13.79) 7/52 (13.46) .523
Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral
equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N
= 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141); HDL = high-
density lipoprotein; LDL = low-density lipoprotein.
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Page 7 of 10Figure 3 Kaplan-Meier survival analysis of time to relapse by dose group. Figure 3 illustrates the survival curves for time to relapse by dose
group. Relapse or “psychotic exacerbation” was defined as 1) an increase of any BPRS positive symptom item to a score >4, with an absolute
increase ≥2 for the specific item since randomization, 2) an increase of any BPRS positive symptom item to a score >4, with an absolute increase
≥4 on the positive symptom subscale since randomization; or 3) hospitalization as the result of worsening of positive psychotic symptoms.
Median time to relapse not reported because no group had >50% rate of relapse. Abbreviations: OLZ LAI = olanzapine long-acting injection;
OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI
405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI
300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
OLZ LAI 150
OLZ LAI 405
OLZ LAI 300
ǻ PANSS total = 6.5366 - 0.4249dose
Figure 4 Regression scatterplot of mean change in PANSS total score (LOCF) by dose. Figure 4 shows the scatterplot, regression line, and
resulting equation for the relationship between endpoint PANSS total score change and dose (R
2 = 0.0133). In the equation, “dose” refers to the
calculated oral equivalent daily dose (10.7, 14.5, or 21.4 mg/day), not the actual injected dose. Abbreviations: OLZ LAI = olanzapine long-acting
injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140);
OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ
LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
Hill et al. BMC Psychiatry 2011, 11:28
http://www.biomedcentral.com/1471-244X/11/28
Page 8 of 10Figure 5 Rates of overall discontinuation and discontinuation due to efficacy-related reasons by dose group. Figure 5 illustrates the
rates of overall discontinuation (NNT = 9 high vs. low dose) and discontinuation for efficacy-related reasons (NNT = 8 high vs. low dose; NNT =
13 high vs. medium dose) by dose group. Efficacy-related reasons includes lack of efficacy and/or any psychiatric adverse event (e.g.,
“schizophrenia”, “paranoid disorder,” etc.). Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose
olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose
olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose
olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
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Figure 6 Kaplan-Meier survival analysis of time to all-cause discontinuation by dose group. Figure 6 shows the survival curves for time to
all-cause discontinuation by dose group. Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose
olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine
LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI,
300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
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Page 9 of 10the study design affects how safety and efficacy data are
interpreted; specifically, some patients experienced a
change in dose from the stabilization period to the
maintenance period. Patients who had been stabilized
on 20 mg/day oral olanzapine and subsequently rando-
mized to the lowest olanzapine LAI dose (approximately
10 mg/day oral equivalent) essentially experienced a
dose decrease. Likewise, patients stabilized on 10 mg/
day oral olanzapine and subsequently randomized to the
highest olanzapine LAI dose (approximately 20 mg/day
oral equivalent) experienced a dose increase. These dose
changes make interpreting our findings regarding safety
and efficacy more difficult.
Conclusions
Analyses of several clinically important safety and effi-
cacy measures revealed significant dose-associated
changes for olanzapine LAI, with the highest dose gen-
erally showing greater efficacy (e.g., longer time to
relapse) as well as greater changes in certain safety mea-
sures (e.g., greater weight gain). When considering olan-
zapine LAI, as with all antipsychotics, it is important to
carefully consider the potential benefits and risks for an
individual patient.
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